The tax area 丨 The industrial added value of the Zhuhai Biomedical Regulations in the first half of the year increased by 19.5%, and the "tax power" leveraged the enterprise to break through the innovation customs

Editor's note:

In 2022, the new combined tax support policy has become a "Dinghai God Needle" that stabilizes the economic market throughout the year. As one of the most open and economic vitality areas in China, 2022 is also the third anniversary of the implementation of the "Development Planning of the Guangdong -Hong Kong -Macao Greater Bay Area". To this end, Southern Finance and Economics All -Media Group planned to launch a special report of the "Tax Eye Watch Area" to observe the city samples with taxes, focus on the regional pillar industry, and insight into the economic development of 9 cities in the Mainland in the Greater Bay Area, explore the high of the Guangdong -Hong Kong -Macao Greater Bay Area high New path of quality development. Stay tuned.

Southern Finance All Media Reporter Peng Minjing Zhuhai Report

"Although the company faces many problems such as rising raw materials and transportation costs, dilemma of electricity limit, and repeated epidemic conditions, the company has maintained a steady growth trend in the first half of this year, and the total assets increased by 4.53%year -on -year." On August 12, Zhuhai Rundu Pharmaceutical Pharmaceutical Shi Shenhua, the financial leader of shares (referred to as "Rundu Pharmaceutical"), told Southern Finance and Economics reporters that the pharmaceutical industry challenges and opportunities coexist. Next, they will use the national tax reduction policy to actively respond to changes in internal and external environments.

Under the pressure of demand contraction, supply shock, and expected weakness, Zhuhai's biomedical industry still rises against the trend, becoming an important engine to promote the rapid economic growth of Zhuhai. According to data from the Zhuhai Statistics Bureau, in the first half of the year, Zhuhai's city's increase in industrial added value above designated size was 74.861 billion yuan, an increase of 8.5%year -on -year. Among them, Zhuhai's biomedicine has accumulated a total of 50.024 billion yuan in industrial added regulations, an increase of 19.5%year -on -year.

With the implementation of a package of tax and fees for the rejuvenation of enterprises, the biopharmaceutical industry in Zhuhai has shown a steady progress, showing a steady development trend. VAT invoice data show that in the first half of this year, the medical and health industry market in Zhuhai continued to be active, achieving sales revenue of 25.479 billion yuan, an increase of 1.36%year -on -year.

A number of people in the biomedical industry told a reporter from Southern Finance and Economics that in recent years, the normalization and institutionalization of pharmaceutical collection and innovative pharmaceutical medical insurance negotiations, medical insurance, medical, and pharmaceutical linkage reforms are becoming more and more complete. The high -quality development path driven by scientific and technological innovation, green low -carbon, and industrial gathering will become the main tone of the future development of the pharmaceutical industry.

"The tax department continues to improve the level of taxation services, accurately implement preferential taxes and fees, and continuously create a good tax policy environment and business environment. It will effectively help biomedical companies to improve their innovative research and development capabilities and industrial competitiveness." Experts interviewed said.

The "tax reduction account" behind pharmaceutical companies

At present, Zhuhai has basically formed the biomedical and health industry system with the support of the medical manufacturing industry, the support of the medical equipment, the characteristics of the traditional Chinese medicine, the precise nutrition and cosmetics, and the first batch of strategic emerging industrial clusters of the National Development and Reform Commission for the National Development and Reform Commission Essence There are 87 companies in the cluster, including 9 listed companies. According to the plan, by 2035, the total output value of Zhuhai's biomedical industry will reach 120 billion yuan.

In fact, Zhuhai has always regarded biomedicine as a key development industry, attracting enterprises with a high -quality business environment, retaining enterprises with efficient tax services, and striving to provide a strong backing for the development of pharmaceutical companies.

For biomedical companies, the company needs to invest a lot of research and development funds, and the policy dividend of "real gold and silver" effectively reduces the burden on corporate taxes and provides a strong guarantee for corporate funds.

Zhuhai Federal Pharmaceutical Co., Ltd. (referred to as "Federal Pharmaceutical") is an enterprise jointly invested by Zhuhai Pharmaceutical Company and Hong Kong Federal Pharmaceutical Factory Co., Ltd.. In the first half of this year, the research and development costs of federal pharmaceuticals exceeded 58 million yuan.

"With the introduction of the policy of deducting the policy before the R & D expenses, our company has benefited a lot. In 2021, the company's research and development expenses plus deduction policy deducting the policy of reducing the company's income tax exceeded 34 million yuan. In addition, we are high -tech enterprises, 2021, 2021, 2021, 2021, 2021, 2021, 2021 The annual high -tech enterprise reducing corporate income tax is nearly 77.2 million yuan. "Li Tiancai, the head of the federal pharmaceutical finance, calculated the company's" tax reduction account ".

Thanks to this, in the first half of this year, federal pharmaceutical production and operation steadily expanded, and the output of raw materials increased by 27%year -on -year. The output of insulin and Peinan -class preparations increased by 144%year -on -year, and sales revenue increased by 25%year -on -year. Especially in the 2021 insulin special national mining, 7 federal pharmaceuticals were bidd, and their insulin products were highly recognized.

From the perspective of industry insiders, the biomedical and health industries in Zhuhai still have problems such as insufficient industrial chain structure, the construction of public service platforms to be strengthened, and insufficient supply of high -level talents.

"Zhuhai's biomedicine and health industries are mainly pharmaceutical manufacturing enterprises. Chemical drugs in product structure account for more than 80%, and the proportion of generic drugs is high. Lack of raw materials processing, technology research and development, medical distribution, medical services and other industries such as upstream and downstream Supporting enterprises, enterprises in the city are still accustomed to completing various processes of product production independently. The segmentation of the upstream and downstream labor of the industrial chain is not high, the professional cooperation production is insufficient, and there is a discrete. " Dean Mei Yaomin said.

Optimizing the business environment has become a password for Zhuhai to attract biomedical agglomeration and build a "new highland" in the biomedical industry.

It is understood that in order to follow up with the progress of key construction projects in a timely manner, the Zhuhai Taxation Department vigorously promotes the Guangdong's tax industry chain Zhilian platform, actively guides taxpayers to connect supply and demand through the intellectual connection platform, improve the industrial chain, and promote the scale, clusterization, and green development of pharmaceutical enterprises. Essence In the process of promoting the key construction projects of the biomedical industry, Zhuhai's taxation department sort out various tax preferential policies in time to provide accurate tax policy counseling for the development characteristics of the biomedical industry project. Tax and benefit policy to help enterprises achieve "leading" technology

The rise of the Zhuhai biomedical industry is not accidental, but the inevitable result of the accumulation of innovation elements.

In order to further encourage enterprises to increase investment in R & D, the country has introduced a series of R & D expenses to deduct the new policy in recent years. In 2021, the central government increased the proportion of research and development expenses of manufacturing enterprises to 100%. On this basis, this year, it proposed that the proportion of science and technology small and medium -sized enterprises increased from 75%to 100%, and further increased the implementation of R & D expenses and deducting policy implementation.

"In the past two years, Rundu Pharmaceutical enjoyed a tax revenue of high -tech enterprises for tax revenue and exemption of 14.78 million yuan in income tax, and enjoyed 159.74 million yuan in R & D expenses. These countries' tax discount dividends greatly alleviated the company's development pressure." Shi Shenhua said.

At present, Rundu Pharmaceutical has formed an industrial chain integrated product line with anti -hypertensive Salin series products, anti -digestive ulcer pump inhibitors series products, with intestinal soluble and slow -controlled release agents (micro pill preparation products, etc. ) The series of products, strive to build a leading enterprise with special products such as domestic production of micro -pill preparations, anti -hypertensive sand tank drugs, anti -digestive ulcer pump inhibitors.

On August 9, Lizhu Pharmaceutical Group Co., Ltd. ("Lizhu Group") announced the financial report data in the first half of 2022. The financial report shows that the Lizhu Group achieved operating income of 6.302 billion yuan in the first half of this year, an increase of 1.08%year -on -year; the net profit attributable to shareholders after deducting non -recurring profit or loss was 1.046 billion yuan, an increase of 13.73%year -on -year. The positive growth of revenue and net profit also means that the two -wheel drive strategy of "Innovation Pharmaceutical+High Bargaining Complex Preparation" performed by Lizhu Group effectively drives the company's main business business for long -term sustainable development.

Lizhu Group also continues to increase in research and development. The financial report shows that in the first half of the year, the total expenditure used by Lizhu Group for R & D was 639 million yuan, an increase of 17.22%year -on -year, and the proportion of R & D investment accounted for 10.14%. As of the first half of this year, the company had 7 complex preparations such as microspheres in the research projects, 7 biopharmaceutical research projects, and nearly 30 other chemicals.

However, Wu Qian, the financial leader of Lizhu Group, also admitted to the reporter of the Southern Finance and Economics that affected by factors such as the bidding of medical insurance, especially the industry policies with volume procurement, the price of the original patent drug of Lizhu Group from 156 yuan/branch dropped from 156 yuan/support 71 yuan/support. In addition, due to the impact of the epidemic, medical staff tilted towards the front line of epidemic prevention, and patients with other diseases declined, and conventional prescriptions decreased.

To this end, Lizhu Group will continue to strengthen research and development innovation in the second half of the year. Through improving the research and development innovation system, actively introducing and developing high -end talents, carrying out overseas innovative drug cooperation and introduction, strengthening market research and evaluation, improving the research and development project specifications and risk prevention and control, etc., the core varieties are achieved. At the same time, the active response to the decline in medical insurance prices on the company's performance has brought about the company's performance, and the implementation of "price conversion" to increase hospital coverage and product sales.

"Last year, Lizhu Group shared the R & D fee and the deduction of 660 million yuan. As of August this year, the group and its subordinate companies received a value -added tax reserved tax refund of 98.77 million yuan, and the total taxes and fees for the total tax and fees were 2100 10,000 yuan really relieves the pressure of our corporate funds, and provides strong support and guarantee for the next production and operation and research and development investment. "Wu Qian said.

- END -